

DAFTAR PUSTAKA

- Agustí A, Soler JJ, Molina J, et al., 2012, Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? *COPD* 9(5):492–498.
- Alatas H, Karyomanggolo WT, Musa DA, Oesman IN, Boediarso A., 1995, *Desain penelitian: pandangan umum*. Cit. Sastroasmoro S, Ismael S (editor). *Dasar-dasar metodologi penelitian klinis*, Bina Rupa Aksara, Jakarta.
- Alison JA, McKeough ZJ, Johnston K, et al, 2017, Australian and New Zealand Pulmonary Rehabilitation Guidelines, *Respirology* 22(4): 800-19.
- American Academy of Family Physicians, 2016, *COPD and Asthma: Differential Diagnosis*, Boehringer Ingelheim Pharmaceuticals.
- American Lung Association, 2018, The Connection Between Pneumonia and Lung Disease, <https://www.lung.org/blog/pneumonia-and-lung-disease#:~:text=COPD%20and%20asthma%20can%20cause,to%20infections%20like%20pneumococcal%20pneumonia>. Diakses pada 03 Maret 2023 pukul 00.12 WIB.
- American Lung Association, 2022, Bronchiectasis, <https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/bronchiectasis/> Diakses pada 11 Maret 2023 pukul 11.14 WIB.
- Anggita.T. Nuari & Masturoh I, 2018, *Metodologi Penelitian Kesehatan*: Jakarta.
- Barnes P. J., 2000, Chronic obstructive pulmonary disease, *The New England journal of medicine*, 343(4): 269–280.
- Bartlett, R. H., Ogino, M. T., Brodie, D., McMullan, D. M., Lorusso, R., MacLaren, G., Stead, C. M., Rycus, P., Fraser, J. F., Belohlavek, J., Salazar, L., Mehta, Y., Raman, L., & Paden, M. L., 2020, Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure, *ASAIO journal* (American Society for Artificial Internal Organs : 1992), 66(5): 472–474.
- Bellani, G., Laffey, J. G., Pham, T., Madotto, F., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., Bumbasirevic, V., Piquilloud, L., van Haren, F., Larsson, A., McAuley, D. F., Bauer, P. R., Arabi, Y. M., Ranieri, M., Antonelli, M., Rubenfeld, G. D., Thompson, B. T., Wrigge, H., ... ESICM Trials Group, 2017, Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study, *American journal of respiratory and critical care medicine*, 195(1): 67–77.
- Berger, R., & Smith, D., 1988, Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway obstruction, *The American review of respiratory disease*, 138(3): 624–629.
- Bertoletti L, Quenet S, Laporte S, et al., 2013, Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry, *Respir Res* 2013 14: 75.

- Bilton D, Jones AL, 2011, European Respiratory Monograph: Bronchiectasis, *European Respiratory Society* 52:1–10.
- Black P. N., 2008, Role of antibioticICS in the management of chronic obstructive pulmonary disease, *Expert review of respiratory medicine* 2(2), 235–243.
- Boyd CM, Fortin M., 2011, Future of multimorbidity research: How should understanding of multimorbidity inform health system design? *Public Health Rev* 32:451–74
- Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., Brodie, D., Beckman, J. A., Kirtane, A. J., Stone, G. W., Krumholz, H. M., & Parikh, S. A., 2020, Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic, *Journal of the American College of Cardiology*, 75(18): 2352–2371.
- Cardiovascular Institute of the South, 2017, COPD and Heart Failure: What are the Symptoms and how are They Related? <https://www.cardio.com/blog/copd-and-heart-failure-what-are-the-symptoms-and-how-are-they-related#:~:text=In%20severe%20cases%20of%20COPD,condition%20known%20as%20pulmonary%20hypertension.> Diakses pada 01 Maret 2023 pukul 15.15 WIB.
- Cazzola M, Rogliani P, Ruggeri P, et al., 2013, Chronic treatment with indacaterol and airway response to salbutamol in stable COPD, *Respir Med* 107(6): 848-53.
- Cazzola M, Calzetta L, Page C, et al., 2015, Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis, *Eur Respir Rev* 24(137): 451-61.
- Calverley, P. M., & Walker, P., 2003, Chronic obstructive pulmonary disease, *Lancet (London, England)*, 362(9389): 1053–1061.
- CDC, 2012, Chronic Obstructive Pulmonary Disease Among Adults, <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm> diakses pada Rabu, 05 Oktober 2022 pukul 11.13 WIB.
- CDC, 2018, Tobacco Product Use Among Adults, <https://www.cdc.gov/mmwr/volumes/67/wr/mm6744a2.htm> diakses pada Rabu, 05 Oktober 2022 pukul 14.24 WIB.
- Chan-Yeung MA, Buncio DY., 1984, Leucocyte counts, smoking and lung function, *Am J Med* 76:31-7
- Chetta A, Olivieri D., 2012, The COPD assessment test in the evaluation of chronic obstructive pulmonary disease exacerbations, *Expert Rev Respir Med* 6:373–5.
- Cho, J., Lee, C. H., Kim, D. K., Hwang, H. G., Kim, Y. I., Choi, H. S., Park, J. W., Yoo, K. H., Jung, K. S., Lee, S. D., & KOLD and KOCOSS Investigators, 2020, Impact of gender on chronic obstructive pulmonary disease outcomes: a propensity score-matched analysis of a prospective cohort study, *The Korean journal of internal medicine*, 35(5), 1154–1163.
- Chrystyn, H., Mulley, B., & Peake, M., 1988, Dose response relation to oral theophyllin in severe chronic obstructive airways disease, *BMJ*, 297(6662): 1506-1510.

- Chung K. F., 2006, Salmeterol/fluticasone combination in the treatment of COPD, *International journal of chronic obstructive pulmonary disease* 1(3), 235–242.
- Cooper C. B., 2009, Airflow obstruction and exercise, *Respiratory medicine* 103(3): 325–334.
- Cosio BG, Shafiek H, Iglesias A, et al, 2016, Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients with Severe COPD: A Pilot Clinical Trial, *Chest* 150(1): 123-30.
- Cukic, V., Lovre, V., Dragisic, D., & Ustamujic, A., 2012, Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Differences and Similarities, *Materia socio-medica* 24(2), 100–105.
- Dalimunthe, R. A., 2019, Hubungan Antara *COPD Assessment Test* (CAT) dengan Faal Paru pada Pasien Penyakit Paru Obstruktif Kronis di Rumah Sakit Dr. Pirngadi Medan Tahun 2018, Skripsi, Fakultas Kedokteran, Universitas Muhammadiyah Sumatera Utara, Medan.
- Decramer M. L., Chapman, K. R., Dahl R., dkk., 2013, Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study, *Lancet Respir Med* 1:524.
- Devereux G, Cotton S, Fielding S, et al, 2018, Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial, *JAMA* 320(15): 1548-49.
- De Gracia J, Rodrigo MJ, Morell F, et al, 1996, IgG subclass deficiencies associated with bronchiectasis, *Am J Respir Crit Care Med* 153:650–655.
- DiPiro, Yee, G. C., Posey, M., Haines, S. T., Nolin, T. D., Ellingrod, V., 2020, *Pharmacotherapy A Pathophysiology Approach*, Eleventh Ed., p. 1227-1264.
- Dransfield MT, McAllister DA, Anderson JA, dkk., 2018, Beta blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk an Observational Substudy of SUMMIT, *Ann Am Thorac Soc* 15(5): 608-14.
- Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., Brodie, D., Beckman, J. A., Kirtane, A. J., Stone, G. W., Krumholz, H. M., & Parikh, S. A., 2020, Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic, *Journal of the American College of Cardiology*, 75(18): 2352–2371.
- Dyussenbayev, A., 2017, Age Periods of Human Life, *Advances in Social Sciences Research Journal*, 4(6).
- Effing TW, Vercoulen JH, Bourbeau J, et al., 2016, Self-management intervention: International Expert Group consensus, *Eur Respir J* 48(1): 46-54.
- Eisner, M. D., Blanc, P. D., Omachi, T. A., Yelin, E. H., Sidney, S., Katz, P. P., Ackerson, L. M., Sanchez, G., Tolstykh, I., & Iribarren, C., 2011, Socioeconomic

- status, race and COPD health outcomes, *Journal of epidemiology and community health*, 65(1), 26–34.
- Ekstrom M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D., 2016, Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy, *Cochrane Database Sys Rev* 2016 11: CD006429.
- Elhefny RA, Elessawy AF, 2015, Assessment of chronic obstructive pulmonary disease in rural women, *Egypt J Chest Dis Tuberc* [Internet] 64:343–6.
- Feliz-Rodriguez, D., Zudaire, S., Carpio, C., Martínez, E., Gómez-Mendieta, A., Santiago, A., Alvarez-Sala, R., & García-Río, F., 2013, Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value, *Canadian respiratory journal*, 20(5): e92–e97.
- Ferguson GT, Taylor AF, Thach C, dkk., 2016, Long-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study, *Chronic Obstr Pulm Dis*. 3(4):716–728.
- Ferguson, G. T., Tashkin, D. P., Skärby, T., Jorup, C., Sandin, K., Greenwood, M., Pemberton, K., & Trudo, F., 2017, Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study, *Respiratory medicine* 132, 31–41.
- Fimognari, F. L., Loffredo, L., Di Simone, S., Sampietro, F., Pastorelli, R., Monaldo, M., Violi, F., & D'Angelo, A., 2009, Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease, *Nutrition, metabolism, and cardiovascular diseases: NMCD*, 19(9), 654–659.
- Fletcher, M.J., Upton, J., Taylor-Fishwick, J. et al., 2011, COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population, *BMC Public Health* 11: 612.
- García-Sidro, P., Naval, E., Martinez Rivera, C., Bonnin-Vilaplana, M., Garcia-Rivero, J. L., Herrejón, A., Malo de Molina, R., Marcos, P. J., Mayoralas-Alises, S., Ros, J. A., Valle, M., Esquinas, C., Barrecheguren, M., & Miravittles, M., 2015, The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations, *Respiratory medicine* 109(12), 1546–1552.
- Gattinoni, L., Chiumello, D., Caironi, P., Busana, M., Romitti, F., Brazzi, L., & Camporota, L., 2020), COVID-19 pneumonia: different respiratory treatments for different phenotypes?, *Intensive care medicine*, 46(6), 1099–1102.
- Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ, 2015, Indacaterol, a once daily beta2 -agonist, versus twice-daily beta2 agonist or placebo for chronic obstructive pulmonary disease, *Cochrance Database Syst Rev* 1: CD010139.

- Ghobadi, H., Ahari, S. S., Kameli, A., & Lari, S. M., 2012, The Relationship between COPD Assessment Test (CAT) Scores and Severity of Airflow Obstruction in Stable COPD Patients, *Tanaffos* 11(2), 22–26.
- Gil, H. I., Zo, S., Jones, P. W., Kim, B. G., Kang, N., Choi, Y., Cho, H. K., Kang, D., Cho, J., Park, H. Y., & Shin, S. H., 2021, Clinical Characteristics of COPD Patients According to COPD Assessment Test (CAT) Score Level: Cross-Sectional Study, *International journal of chronic obstructive pulmonary disease*, 16, 1509–1517.
- GINA, 2022, *Global Strategy for Asthma Management and Prevention*, USA: Global Initiative for Asthma.
- GOLD, 2022, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, USA: Global Initiative for Chronic Obstructive Lung Disease, Inc.
- Grieco DL, Bongiovanni F, Chen L, Menga LS, Cutuli SL, Pintaudi G, Carelli S, Michi T, Torrini F, Lombardi G, Anzellotti GM, De Pascale G, Urbani A, Bocci MG, Tanzarella ES, Bello G, Dell'Anna AM, Maggiore SM, Brochard L, Antonelli M., 2020, Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies, *Crit Care* 24(1):529.
- Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., & Mannino, D. M., 2006, Global burden of COPD: systematic review and meta-analysis. *The European respiratory journal*, 28(3), 523–532.
- Hay, J. G., Stone, P., Carter, J., Church, S., Eyre-Brook, A., Pearson, M. G., Woodcock, A. A., & Calverley, P. M., 1992, Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. *The European respiratory journal*, 5(6): 659–664.
- Huang, Y. Q., Gou, R., Diao, Y. S., Yin, Q. H., Fan, W. X., Liang, Y. P., Chen, Y., Wu, M., Zang, L., Li, L., Zang, J., Cheng, L., Fu, P., & Liu, F., 2014, Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy, *Journal of Zhejiang University Science B* 15(1), 58–66.
- Jenkins, S. C., Heaton, R. W., Fulton, T. J., & Moxham, J., 1987, Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. *Chest*, 91(6): 804–807.
- Jin, Jian-Min; Sun, Yong-Chang, 2017, Allergy and Chronic Obstructive Pulmonary Disease, *Chinese Medical Journal* 130(17).
- Jones PW, Agusti A. G. N., 2006, Outcomes and markers in the assessment of chronic obstructive pulmonary disease, *Eur respir J* 27: 822-32.
- Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline leidy N., 2009, Development and first validation of the COPD assessment test. *Eur Respir J*. 34(3):648–654.
- Jones, P. W., Tabberer, M., & Chen, W. H., 2011, Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores, *BMC pulmonary medicine* 11(42).

- Jones PW, Brusselle G, Dal Negro RW, et al., 2011, Properties of the COPD assessment test in a cross-sectional European study. *Eur Respir J*.38(1):29–35.
- Junaidi, Junaidi, 2015, *Statistik Uji Kruskal-Wallis*. 10.6084/M9.FIGSHARE.1439656.
- Karner C, Chong J, Poole P, 2014, tiotropium versus placebo for chronic obstructive dpulmonary disease, *Cochrane Database Syst Rev* 7(7): CD009285.
- Kelly JL, Bamsey O, Smith C, et al., 2012, Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients., *Respiration*: 84 (3):193–199.
- Kemenkes, 2019, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 01. 07/MENKES/687/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronik.
- Kew KM, Mavergames C, Walters JA, 2013, Long-acting beta2-agonists for chronic obstructive pulmonary disease, *Cochrane Database Syst Rev* 10(10): CD010177.
- Kirkil G, Muz M. H., 2008, B Group Vitamin Levels in Patients with Chronic Obstructive Pulmonary Disease and The Relation Between Pulmonary Functions, *Tur Toraks Der* 9:88-92.
- Kostikas K, Greulich T, Mackay AJ, et al., 2019, Treatment response in COPD: does FEV(1) say it all? A post hoc analysis of the CRYSTAL study. *ERJ Open Res* 9(5): 492-98.
- Kwon, N., Amin, M., Hui, D. S., Jung, K. S., Lim, S. Y., Ta, H. D., Thai, T., Yunus, F., & Jones, P. W., 2013, Validity of the COPD assessment test translated into local languages for Asian patients, *Chest*, 143(3): 703–710.
- Lechowicz, K., Drożdżal, S., Machaj, F., Rosik, J., Szostak, B., Zegan-Barańska, M., Biernawska, J., Dabrowski, W., Rotter, I., & Kotfis, K., 2020, COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection, *Journal of clinical medicine*, 9(6), 1917.
- Lin SM, Liu KX, Lin ZH, Lin PH, 2017, Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systemic review and meta-analysis, *Respir Med* 2017, 131: 58-64.
- Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Singh, D., Tabberer, M., Wise, R. A., Pascoe, S. J., & IMPACT Investigators, 2018, Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD, *The New England journal of medicine*, 378(18), 1671–1680.
- Lipworth, B. J., McDevitt, D. G., & Struthers, A. D., 1990, Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy. Protection by conventional doses of spironolactone but not triamterene, *Chest*, 98(4): 811–815.
- Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, dkk., 2013, High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross Sectional Study, *PloS One* 8(6): e68034.

- Lowe, K. E., Make, B. J., Crapo, J. D., Kinney, G. L., Hokanson, J. E., Kim, V., Iyer, A. S., Bhatt, S. P., Hoth, K. F., Holm, K. E., Wise, R., DeMeo, D., Foreman, M. G., Stone, T. J., & Regan, E. A., 2018, Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary disease, *ERJ open research*, 4(4), 00069-2018.
- Ma, X., Liang, M., Ding, M., Liu, W., Ma, H., Zhou, X., & Ren, H., 2020, Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS), *Medical science monitor: international medical journal of experimental and clinical research*, 26, e925364.
- Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA., 2012, Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations, *Am J Respir Crit Care Med*, 185(11):1218–1224.
- Mackay AJ, Kostikas K, Roche N, et al., 2020, Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. *Respir Res* 21(1):93.
- MacLaren, G., Fisher, D., & Brodie, D., 2020, Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation, *JAMA*, 323(13): 1245–1246.
- MacNee W., 2016, Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease?, *Annals of the American Thoracic Society*, 13 Suppl 5, S429–S437.
- Maltais F, Bjermer L, Kerwin EM, et al, 2019, Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial, *Respir Res* 20(1): 238.
- Manson, S. C., Brown, R. E., Cerulli, A., Fernandez, C., 2009, The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use, *Respiratory Medicine* 103(7): 975-994.
- Marchetti N, Criner GJ, 2015, Surgical Approaches to treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation, *Semin Respir Crit Care Med* 36(4): 592-608.
- Martinez, F. J., Calverley, P. M., Goehring, U. M., Brose, M., Fabbri, L. M., & Rabe, K. F., 2015, Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial, *Lancet* (London, England) 385(9971): 857–866.
- McKay, S. E., Howie, C. A., Thomson, A. H., Whiting, B., & Addis, G. J., 1993, Value of theophylline treatment in patients handicapped by chronic obstructive lung disease, *Thorax*, 48(3), 227–232.
- McKeever TM, Hearson G, Housley G, et al, 2016, Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study, *Thorax* 71(3): 210-5.

- Melani AS, 2015, Long acting muscarinic antagonists, *Expert Rev Clin Pharmacol* 8(4): 479-501.
- Michalski, J. M., 2011, *Prostaglandin E2 signaling in human lung fibroblasts: mechanisms of signal attenuation and implications in chronic lung diseases*. University of Nebraska Medical Center.
- Milanowska, J., Mackiewicz, B., Węgorowski, P., Milanowski, J., Milanowski, P., & Makara-Studzińska, M., 2017, The quality of life of farmers with chronic obstructive pulmonary disease (COPD). *Annals of agricultural and environmental medicine: AAEM*, 24(2): 283–287.
- Miravittles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P., 2012, Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis, *Eur Respir J* 39(6): 1354-60.
- NIH, 2022, What is COPD? <https://www.nhlbi.nih.gov/health/copd> diakses pada Kamis, 06 Oktober 2022 pukul 21.43 WIB.
- Nishi SPE, Maslonka M, Zhang W, Kuo YF, Sharma G., 2018, Pattern and adherence to maintenance medication use in medicare beneficiaries with chronic obstructive pulmonary disease: 2008-2013, *Chronic Obstr Pulm Dis* 5(1):16–26.
- Nugraha C.A, Ika, 2011, Hubungan Derajat Berat Merokok Berdasarkan Indeks Brinkman Dengan Derajat Berat PPOK, *Stikespku*, 7 (3).
- O'Donnell, D. E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Make, B., & Magnussen, H., 2004, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD, *The European respiratory journal*, 23(6): 832–840.
- O'Donnell, D. E., Sciurba, F., Celli, B., Mahler, D. A., Webb, K. A., Kalberg, C. J., & Knobil, K., 2006, Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD, *Chest*, 130(3): 647–656.
- Osman, S., Ziegler, C., Gibson, R., Mahmood, R., & Moraros, J., 2017, The Association between Risk Factors and Chronic Obstructive Pulmonary Disease in Canada: A Cross-sectional Study Using the 2014 Canadian Community Health Survey, *International journal of preventive medicine*, 8(86).
- Papaioannou M, Pitsiou G, Manika K, et al., 2014, COPD assessment test: A simple tool to evaluate disease severity and response to treatment, *COPD J Chronic Obstr Pulm* 11(5):489-495.
- PDPI, 2004, *PPOK: Pedoman Diagnosa dan Penatalaksanaan di Indonesia*, Jakarta: PDPI.
- Poole P, Ching J, Cates CJ, 2015, Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease, *Cochrane Database Syst Rev* (7): CD001287.
- Poole, P., Sathananthan, K., & Fortescue, R., 2019, Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease, *The Cochrane database of systematic reviews*, 5(5), CD001287.
- Pothirat C, Chaiwong W, Limsukon A, et al., 2015, Detection of acute deterioration in health status visit among COPD patients by monitoring COPD

- assessment test score. *Int J Chron Obstruct Pulmon Dis.* 10:277–282 Ram, F. S., Jones, P. W., Castro, A. A., De Brito, J. A., Atallah, A. N., Lacasse, Y., Mazzini, R., Goldstein, R., & Cendon, S. (2002). Oral theophylline for chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*, 2002(4), CD003902.
- Price, Wilson, 2006, *Patofisiologi Vol 2; Konsep Kllinis Proses-proses Penyakit*, Penerbit Buku Kedokteran, EGC, Jakarta.
- Putra, G.N, & Artika, I.D., 2013, Diagnosis dan Tata Laksana Penyakit Paru Obstruktif Kronik (PPOK), *E-Jurnal Medika Udayana* Vol.2
- Rabe, K. F., Calverley, P. M. A., Martinez, F. J., & Fabbri, L. M., 2017, Effect of roflumilast in patients with severe COPD and a history of hospitalisation, *The European respiratory journal* 50(1), 1700158.
- Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M., MacLaren, G., Brodie, D., & Shekar, K, 2020, Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases, *The Lancet Respiratory medicine*, 8(5):518–526.
- Ray R, Tombs L., Naya I, Compton C, Lipson DA, Boucot I, 2019, Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials, *Pulm Pharmacol Ther* 57:101802.
- Reilly JJ SE, Shapiro SD. Chronic obstructive pulmonary disease. In: Kasper B, Longo, Fauci, Hauser, Jameson, ed. *Harrison Principle of Internal Medicine*, 2011, *Mc Graw-Hill* 18: 1547-53.
- Remmelink, M., De Mendonça, R., D'Haene, N., De Clercq, S., Verocq, C., Lebrun, L., Lavis, P., Racu, M. L., Trépant, A. L., Maris, C., Rorive, S., Goffard, J. C., De Witte, O., Peluso, L., Vincent, J. L., Decaestecker, C., Taccone, F. S., & Salmon, I., 2020, Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients, *Critical care* (London, England), 24(1): 495.
- Renkema TE, Schouten JP, Koeter GH, Postma DS, 1996, Effects of long-term treatment with corticosteroid is COPD, *Chest* 109(5): 1156-62.
- Rice KL, Rubins JB, Lebahn F, dkk., 2000, Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial, *Am J Respir Crit Care Med* 162(1):53-67.
- Ringbaek, T., Martinez, G., & Lange, P., 2012, A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation, *COPD*, 9(1): 12–15.
- Roca O, Hernandez G, Diaz-Lobato S, Carratala JM, Gutierrez RM, Masclans JR, 2016, Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure, *Crit Care* 20(1): 109.
- Sedgwick, Philip, 2014, Spearman's rank correlation coefficient, *BMJ: British Medical Journal*.

- Sholikhah, M., Suradi, Aphridasari J., 2019, Pengaruh Pemberian Quercetin Terhadap Kadar Interleukin 8 (IL-8) Dan Nilai COPD Assessment Test (CAT) Pasien Penyakit Paru Obstruktif Kronik (PPOK) Stabil, *Jurnal Respirologi Indonesia* 39(2):103-112.
- Sin, D. D., Stafinski, T., Ng, Y. C., Bell, N. R., & Jacobs, P., 2002, The impact of chronic obstructive pulmonary disease on work loss in the United States. *American journal of respiratory and critical care medicine*, 165(5): 704–707.
- Singh D, Jones PW, Bateman ED, et al., 2014, Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study, *BMC Pulm Med* 18(14):178.
- Siyoto, S. & Sodik A., 2015, *Dasar Metodologi Penelitian*, Yogyakarta: Literasi Media Publishing.
- Sivapalan P, Ingebrigtsen TS, Rasmussen DB, et al, 2019, COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67000 patients with COPD followed for 12 months, *BMJ Open Respir Res* 6(1): e000407.
- Sogaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thomsen RW, 2016, Incidence and Outcomes of patients hospitalized with COPD exacerbation with and without pneumonia, *Int J Chron Obstruct Pulmon Dis* 11(1):455-465.
- Solem, C. T., Sun, S. X., Sudharshan, L., Macahilig, C., Katyal, M., & Gao, X., 2013, Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease, *International journal of chronic obstructive pulmonary disease* (8): 641–652.
- Spruit MA, Singh SJ, Garvey C, et al., 2013, An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation, *Am J Respir*.
- Suastika n. K. W., Aryana I. G. P. S., Kuswardhani R. A. T., 2015, Korelasi Negatif antara Charlson Comorbidity Index dengan Jumlah Limfosit Total dan Kadar Albumin pada Pasien Geriatri, *Jurnal Ilmiah Kedokteran Medicina* 46(3).
- Sudoyo, A. W., Setiyohadi, B., Alwi, I., Simadibrata K., M., Setiati S Aru W, Sudoyo., 2009, *Buku Ajar Ilmu Penyakit Dalam*, Jilid II, Fifth Ed., Jakarta: Interna Publishing.
- Sugiharta, S., 2016, Evaluasi Pengobatan Bronkodilator Dan Kortikosteroid Pada Pasien PPOK Di Instalasi Rawat Inap B RSUP Fatmawati Jakarta Periode Januari 2012-Juni 2013, *Social Clinical Pharmacy Indonesia Journal* 1(1): 76-88.
- Tiberi, S., Torrico, M. M., Rahman, A., Krutikov, M., Visca, D., Silva, D. R., Kunst, H., & Migliori, G. B., 2019, Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation, *Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia*, 45(2).
- Townend J, Mineli C, Mortimer K, et al, 2017, The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study, *Eur Respir J* 2017 49(6).

- Ugoni A., 1993, On the subject of hypothesis testing, *COMSIG review*, 2(2), 45–48.
- Uren, N. G., Davies, S. W., Jordan, S. L., & Lipkin, D. P., 1993, Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure, *European heart journal*, 14(6): 744–750.
- Usmani, O. S., 2015, Inhaled drug therapy for the management of asthma, Prescriber, <https://wchh.onlinelibrary.wiley.com/doi/pdf/10.1002/psb.1303#:~:text=Inhalation%20has%20long%20been%20established,action%20and%20fewer%20side%20effects>. Diakses pada 11 Maret 2023 pukul 11.54 WIB.
- van Dam van Isselt EF, Groenewegen-Sipkema KH, Spruit-van Eijk M, et al, 2014, Pain in patients with COPD: a systematic review and meta-analysis, *BMJ Open* 2014;4: e005898.
- van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., Lloyd-Smith, J. O., de Wit, E., & Munster, V. J., 2020, Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, *The New England journal of medicine*, 382(16): 1564–1567.
- van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA, 2016, Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD, *Cochrane Database Syst Rev* (8): CD010744.
- van Manen JG, Bindels PJ, IJzermans CJ., van der Zee JS, Bottema BJ, Schade E., 2001, Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40, *J Clin Epidemiol* 54:287–293.
- Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., ... & Rodriguez-Roisin, R., 2013, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, *American journal of respiratory and critical care medicine*, 187(4): 347-365.
- Vogelmeier C, Hederer B, Glaab T, dkk., 2011, Tiotropium versus salmeterol for the prevention of exacerbations of COPD, *N Engl J Med* 364:1093.
- Walters JAE, Tan DJ, White CJ, et al., 2018, Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews* 2018 Issue 3.
- Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH, 2014, Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease, *Cochrane Database Syst Rev* (9): CD001288.
- Wang R, Jiang Y, Li X, Zhao Q, Zhu M, Guan Y, Zhao G. Relationships between smoking duration, smoking intensity, hypothetical tobacco price increases, and smoking habit change intention among current smokers in Shanghai, *J Int Med Res.* 2019 Oct;47(10):5216-5228.
- Wedzicha JA, Banerji D, Chapman KR, dkk., 2016, Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD, *N Engl J Med* 374(23):2222–2234.
- Williams D. M., 2018, Clinical Pharmacology of Corticosteroids, *Respiratory care* 63(6), 655–670.

- WHO, 2022, Chronic obstructive pulmonary disease (COPD), [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)) diakses pada 10 Oktober 2022 pukul 22.30 WIB.
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L., Berwanger, O., Cavalcanti, A. B., Dequin, P. F., Du, B., Emberson, J., Fisher, D., Giraudeau, B., Gordon, A. C., Granholm, A., Green, C., Haynes, R., ... Marshall, J. C., 2020, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, *JAMA* 324(13): 1330–1341.
- Wilson ME, Dobler CC, Morrow AS, et al., 2020, Association of Home Noninvasive Positive Pressure Ventilation with Clinical Outcomes in Chronic Obstructive Pulmonary Disease: A Systemic Review and Meta Analysis, *JAMA* 323(5): 455-65.
- Wooton SL, Hil K, Alison JA, et al., 2019, Effects of Ongoing Feedback During a 12-Month Maintenance Walking Program on Daily Physical Activity in People with COPD, *Lung* 197(3): 315-9.
- Wu M, Zhao Q, Chen Y, Fu C, Xu B. 2015, Quality of life and its association with direct medical costs for COPD in urban China, *Health Qual Life Outcomes*
- Yamaya, M., Nishimura, H., Deng, X., Sugawara, M., Watanabe, O., Nomura, K., Shimotai, Y., Momma, H., Ichinose, M., & Kawase, T., 2020, Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells, *Respiratory investigation*, 58(3): 155–168.
- Yasir M, Goyal A, Sonthalia S., 2022, *Corticosteroid Adverse Effects*, Island (FL): StatPearls Publishing; <https://www.ncbi.nlm.nih.gov/books/NBK531462/> diakses pada Rabu, 10 Mei 2023 pukul 22.32 WIB.
- Yonata, Ade, 2016, Pengaruh Komorbid terhadap Terjadinya Bakteriemia MDR Gram Negatif pada Pasien Rawat Inap, *JK Unila* 1(2):211-14.
- Zhou QT, Mei JJ, He B, et al., 2013, Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. *Chin Med J* 126: 11–15.